Harpoon Therapeutics, Inc. announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors. Among his many achievements, Mr. Robbins is credited with leading the highly successful U.S. launch of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in BRAF-mutant metastatic melanoma. Dr. Bailes is a medical oncologist with substantial experience in clinical practice, legislation, public policy and advocacy, and for nearly two decades, served in various executive leadership capacities for ASCO. Mr. Robbins is an accomplished executive with extensive commercial, development and strategic leadership experience during a 20-year career in the pharmaceutical industry, with a specific focus on oncology and hematology products. Most recently, he served at Array Biopharma as the Chief Operating Officer until its acquisition by Pfizer in 2019. Prior to joining Array in 2012, he held management positions at Hospira, Inc., including General Manager and Vice President of the U.S. Alternate Site business unit and Vice President of Corporate Development. Prior to January 2007, he held commercial and leadership positions within Pfizer's oncology division. Additionally, Mr. Robbins has previously served on the board of directors of Fate Therapeutics, Cytograft Tissue Engineering and StemCor Systems. For more than 20 years, Joseph S. Bailes, M.D., served in various leadership capacities, including President, of the American Society of Clinical Oncology (ASCO). During his ten years as Chair of ASCO's Clinical Practice Committee, he led a number of legislative and regulatory initiatives that helped to shape the current environment for regulation and reimbursement of cancer care in the United States. He also served as Chair of the ASCO Government Relations Council, a position that was responsible for ASCO's involvement in legislative, regulatory and public policy matters affecting cancer clinical research and treatment.